




IQVIA brings together exceptional expertise in Cell and Gene Therapy (CAGT) across the Cell and Gene Therapy development lifecycle, to help you increase the efficiency of your program and maximize the value of new therapies.
IQVIA established the Cell and Gene Therapy Center of Excellence in 2019 to develop patient-centered, data driven, hand-tailored strategies for CAGT trials. With the ultimate goal of getting new treatments to patients faster.
Leveraging in-depth therapeutic expertise and operational leadership, IQVIA is prepared to be your CRO partner - providing end-to-end expertise and services, tailored to the needs of CAGT drug development.
Emerging biopharma companies are at the forefront of advanced therapies that are bringing hope to millions. As the CAGT space continues to grow, there are unique opportunities and challenges.
The APAC CAGT landscape, often perceived as uncertain is primed for clinical research and market access success
Insights specific to cell and gene therapy markets
Leveraging virtual approaches and real world data